CO4940454A1 - Nuevo metodo de tratamiento - Google Patents
Nuevo metodo de tratamientoInfo
- Publication number
- CO4940454A1 CO4940454A1 CO98034654A CO98034654A CO4940454A1 CO 4940454 A1 CO4940454 A1 CO 4940454A1 CO 98034654 A CO98034654 A CO 98034654A CO 98034654 A CO98034654 A CO 98034654A CO 4940454 A1 CO4940454 A1 CO 4940454A1
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- insulin
- mammal
- new method
- compound
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9712866.4A GB9712866D0 (en) | 1997-06-18 | 1997-06-18 | Novel method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4940454A1 true CO4940454A1 (es) | 2000-07-24 |
Family
ID=10814527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO98034654A CO4940454A1 (es) | 1997-06-18 | 1998-06-18 | Nuevo metodo de tratamiento |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP0999837A1 (enExample) |
| JP (1) | JP2002504138A (enExample) |
| KR (1) | KR20010013843A (enExample) |
| CN (1) | CN1133431C (enExample) |
| AP (1) | AP1287A (enExample) |
| AR (2) | AR012997A1 (enExample) |
| AU (1) | AU8216398A (enExample) |
| BG (1) | BG104059A (enExample) |
| BR (1) | BR9810444A (enExample) |
| CA (1) | CA2294141A1 (enExample) |
| CO (1) | CO4940454A1 (enExample) |
| DZ (1) | DZ2521A1 (enExample) |
| EA (1) | EA004800B1 (enExample) |
| GB (1) | GB9712866D0 (enExample) |
| HU (1) | HUP0003260A3 (enExample) |
| ID (1) | ID23951A (enExample) |
| IL (1) | IL133143A0 (enExample) |
| IN (1) | IN189723B (enExample) |
| MA (1) | MA26511A1 (enExample) |
| NO (1) | NO996265L (enExample) |
| OA (1) | OA11517A (enExample) |
| PE (1) | PE104499A1 (enExample) |
| PL (1) | PL343123A1 (enExample) |
| SK (1) | SK179399A3 (enExample) |
| TR (1) | TR199903095T2 (enExample) |
| TW (1) | TW587937B (enExample) |
| UA (1) | UA70299C2 (enExample) |
| UY (1) | UY25050A1 (enExample) |
| WO (1) | WO1998057636A1 (enExample) |
| ZA (1) | ZA985237B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
| US7045519B2 (en) | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
| HRP20010773B1 (en) | 1999-04-23 | 2005-06-30 | Smithkline Beecham P.L.C. | Thiazolidinedione derivative and its use as antidiabetic |
| SI1133312T1 (sl) * | 1999-06-21 | 2008-02-29 | Lilly Co Eli | Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina |
| EP1196189A2 (en) | 1999-06-25 | 2002-04-17 | Medtronic MiniMed, Inc. | Multiple agent diabetes therapy |
| US6468507B1 (en) * | 2000-05-01 | 2002-10-22 | Aeropharm Technology, Inc. | Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer |
| GB0023970D0 (en) * | 2000-09-29 | 2000-11-15 | Smithkline Beecham Plc | Novel pharmaceutical |
| WO2002067969A2 (en) | 2001-02-21 | 2002-09-06 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| US6531461B1 (en) | 2001-06-04 | 2003-03-11 | Louis Obyo Obyo Nelson | Medicament for the treatment of diabetes |
| WO2002100396A1 (en) * | 2001-06-07 | 2002-12-19 | Wyeth | COMBINATION OF A PTPase INHIBITOR AND A THIAZOLIDINEDIONE AGENT |
| US6737401B2 (en) | 2001-06-28 | 2004-05-18 | Metronic Minimed, Inc. | Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| CA2503117C (en) | 2002-11-08 | 2010-12-21 | F. Hoffmann-La Roche Ag | Substituted 4-alkoxyoxazol derivatives as ppar agonists |
| US7264813B2 (en) | 2003-09-24 | 2007-09-04 | Nikken Sohonsha Corporation | Therapeutic uses of Dunaliella powder |
| CN102389427A (zh) * | 2011-10-10 | 2012-03-28 | 成都恒瑞制药有限公司 | 含有罗格列酮和盐酸西替利嗪的固体口服制剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1103590C (zh) * | 1993-09-15 | 2003-03-26 | 三共株式会社 | 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作 |
| JPH11510508A (ja) * | 1995-08-10 | 1999-09-14 | ワーナー−ランバート・コンパニー | インシュリン非依存性真性糖尿病患者に投与される外来インシュリンの量を減らす方法 |
| PT859608E (pt) * | 1995-09-18 | 2004-06-30 | Ligand Pharm Inc | Tratamento de niddm com agonistas de rxr |
-
1997
- 1997-06-18 GB GBGB9712866.4A patent/GB9712866D0/en active Pending
-
1998
- 1998-06-15 UA UA99126881A patent/UA70299C2/uk unknown
- 1998-06-15 EA EA200000042A patent/EA004800B1/ru not_active IP Right Cessation
- 1998-06-15 HU HU0003260A patent/HUP0003260A3/hu unknown
- 1998-06-15 IL IL13314398A patent/IL133143A0/xx unknown
- 1998-06-15 PL PL98343123A patent/PL343123A1/xx unknown
- 1998-06-15 AU AU82163/98A patent/AU8216398A/en not_active Abandoned
- 1998-06-15 AP APAP/P/1999/001718A patent/AP1287A/en active
- 1998-06-15 CN CNB988062232A patent/CN1133431C/zh not_active Expired - Fee Related
- 1998-06-15 BR BR9810444-6A patent/BR9810444A/pt not_active IP Right Cessation
- 1998-06-15 TR TR1999/03095T patent/TR199903095T2/xx unknown
- 1998-06-15 CA CA002294141A patent/CA2294141A1/en not_active Abandoned
- 1998-06-15 JP JP50375799A patent/JP2002504138A/ja not_active Ceased
- 1998-06-15 WO PCT/EP1998/003692 patent/WO1998057636A1/en not_active Ceased
- 1998-06-15 KR KR1019997011864A patent/KR20010013843A/ko not_active Ceased
- 1998-06-15 ID IDW991627A patent/ID23951A/id unknown
- 1998-06-15 SK SK1793-99A patent/SK179399A3/sk unknown
- 1998-06-15 EP EP98932169A patent/EP0999837A1/en not_active Withdrawn
- 1998-06-17 ZA ZA9805237A patent/ZA985237B/xx unknown
- 1998-06-17 DZ DZ980131A patent/DZ2521A1/xx active
- 1998-06-17 AR ARP980102883A patent/AR012997A1/es not_active Application Discontinuation
- 1998-06-17 MA MA25122A patent/MA26511A1/fr unknown
- 1998-06-17 AR ARP980102886A patent/AR015894A1/es not_active Application Discontinuation
- 1998-06-17 TW TW087109619A patent/TW587937B/zh not_active IP Right Cessation
- 1998-06-18 IN IN1698DE1998 patent/IN189723B/en unknown
- 1998-06-18 UY UY25050A patent/UY25050A1/es unknown
- 1998-06-18 CO CO98034654A patent/CO4940454A1/es unknown
- 1998-06-18 PE PE1998000535A patent/PE104499A1/es not_active Application Discontinuation
-
1999
- 1999-12-17 NO NO996265A patent/NO996265L/no not_active Application Discontinuation
- 1999-12-17 OA OA9900296A patent/OA11517A/en unknown
-
2000
- 2000-01-06 BG BG104059A patent/BG104059A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL343123A1 (en) | 2001-07-30 |
| NO996265D0 (no) | 1999-12-17 |
| AR015894A1 (es) | 2001-05-30 |
| PE104499A1 (es) | 2000-01-13 |
| EA004800B1 (ru) | 2004-08-26 |
| SK179399A3 (en) | 2000-11-07 |
| TW587937B (en) | 2004-05-21 |
| DZ2521A1 (fr) | 2003-02-08 |
| HUP0003260A3 (en) | 2001-12-28 |
| HUP0003260A2 (hu) | 2001-05-28 |
| CN1133431C (zh) | 2004-01-07 |
| WO1998057636A1 (en) | 1998-12-23 |
| CA2294141A1 (en) | 1998-12-23 |
| IL133143A0 (en) | 2001-03-19 |
| ID23951A (id) | 2000-06-08 |
| CN1260715A (zh) | 2000-07-19 |
| KR20010013843A (ko) | 2001-02-26 |
| AR012997A1 (es) | 2000-11-22 |
| TR199903095T2 (xx) | 2000-08-21 |
| NO996265L (no) | 1999-12-17 |
| BG104059A (en) | 2000-10-31 |
| OA11517A (en) | 2004-02-04 |
| AU8216398A (en) | 1999-01-04 |
| AP1287A (en) | 2004-06-26 |
| AP9901718A0 (en) | 1999-12-31 |
| IN189723B (enExample) | 2003-04-19 |
| MA26511A1 (fr) | 2004-12-20 |
| JP2002504138A (ja) | 2002-02-05 |
| EA200000042A1 (ru) | 2000-08-28 |
| BR9810444A (pt) | 2000-09-05 |
| UY25050A1 (es) | 2000-09-29 |
| ZA985237B (en) | 2000-02-17 |
| EP0999837A1 (en) | 2000-05-17 |
| GB9712866D0 (en) | 1997-08-20 |
| UA70299C2 (en) | 2004-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY129897A (en) | Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus | |
| EA200100541A1 (ru) | Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину и других антидиабетических агентов | |
| AR015894A1 (es) | Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos | |
| EA200000139A1 (ru) | Лечение диабета тиазолидиндионом, средством, стимулирующим секрецию инсулина, и дигуанидом | |
| AR008198A1 (es) | Procedimiento para preparar una composicion farmaceutica de 5-[4-[2-(n- metil-n-(2-piridil)amino)etoxi]bencil]tiazolin-2,4-diona | |
| MY135973A (en) | Modified release compositions comprising 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, optionally in the form of pharmaceutically acceptable derivative | |
| PE108199A1 (es) | Composicion farmaceutica de tiazolidindiona y sulfonilurea | |
| AR016350A1 (es) | Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos | |
| AR016768A1 (es) | COMPOSICIoN FARMACÉUTICA DE 5-(4- (2-(N-METIL-N-(2-PIRIDIL) AMINO)ETOXI)BENCIL)TIAZOLIDIN-2-4-DIONA Y UN SECRETAGOGO DE INSULINA Y USO DE LA MISMA PARA PREPARACIoN DE MEDICAMENTOS | |
| AR013352A1 (es) | Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica. | |
| ECSP982541A (es) | Nuevo metodo de tratamiento ii | |
| CO5150180A1 (es) | Nueva composicion y uso liberacion modificada | |
| ECSP982542A (es) | Nuevo metodo de tratamiento iii | |
| ECSP982593A (es) | Nuevo metodo de tratamiento vi | |
| EA200300423A1 (ru) | Производное тиазолидиндиона и его применение в качестве противодиабетического лекарственного средства | |
| AP1692A (en) | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent. | |
| ECSP982534A (es) | Nuevo metodo de tratamiento | |
| ECSP982592A (es) | Nuevo metodo de tratamiento v | |
| ECSP982535A (es) | Nuevo metodo de tratamiento (i) |